platinum has been researched along with etoposide in 94 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.19) | 18.7374 |
| 1990's | 15 (15.96) | 18.2507 |
| 2000's | 5 (5.32) | 29.6817 |
| 2010's | 24 (25.53) | 24.3611 |
| 2020's | 47 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carter, SK; Muggia, FM; Rozencweig, M; Slavik, M | 1 |
| Bernareggi, A; Castoldi, D; Cimino, G; Colombi, L; Fracasso, ME; Leone, R; Monzani, V; Soresi, E; Tedeschi, M; Usari, T | 1 |
| Bakri, YN; Ezzat, A; Pedersen, P | 1 |
| Bacchi, M; Bassi, P; Belsanti, V; Bisagni, G; Boni, C; Cocconi, G; Lottici, R; Passalacqua, R; Tonato, M | 1 |
| Einhorn, LH; Loehrer, PJ; Seitz, DE; Williams, SD | 1 |
| Schwarz, MA; Snyder, RD | 1 |
| Bosl, GJ; Motzer, RJ; Parker, RJ; Perera, F; Poirier, MC; Reed, E; Shamkhani, H; Tang, D; Tsai, WY | 1 |
| de Boer-Dennert, M; Ma, J; Planting, AS; Schellens, JH; Stoter, G; van der Burg, ME; van Ingen, HE; Verweij, J | 1 |
| Frenkel, EP; Henner, WD; Mickey, BE; Neuwelt, EA; Wiliams, PC | 1 |
| Turrisi, AT | 1 |
| Hill, BT; Hosking, LK; Shellard, SA | 1 |
| Dive, C; Evans, DL; Tilby, M | 1 |
| Hoskins, PJ; Swenerton, KD | 1 |
| Cabanillas, FC; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, JE; Swan, F; Velasquez, W | 1 |
| Jones, WB; Lewis, JL; Schneider, J; Shapiro, F | 1 |
| Hayashi, N; Ikeba, K; Kinoshita, K; Ohokubo, T; Sodemoto, T; Takagi, A; Takeda, S; Yamamoto, T | 1 |
| Berthiot, G; Coninx, P; Desoize, B; Dumont, P; Manot, L | 1 |
| Kano, M; Watanabe, M | 1 |
| Greco, FA | 1 |
| Sugiyama, T | 1 |
| Engelholm, SA; Gronlund, B; Horvath, G; Mäenpää, J; Ridderheim, M | 1 |
| Adjei, AA; Baas, P; Choy, H; Gandara, DR; Gaspar, LE; Goss, G; Lara, PN; Saijo, N; Sangha, R; Schiller, JH; Vokes, EE | 1 |
| Guan, Y; Lin, D; Liu, Y; Liu, Z; Ott, J; Shen, Y; Wu, C; Xu, B; Yu, D; Yuan, P | 1 |
| Aglione, S; Bareggi, C; Blackhall, F; Califano, R; Collovà, E; Farina, G; Fatigoni, S; Galetta, D; Gallerani, E; Garassino, MC; Ghidini, A; La Verde, N; Lo Dico, M; Lorigan, P; Mancuso, A; Martelli, O; Michetti, G; Rossi, A; Saggia, C; Thatcher, N; Torri, V | 1 |
| Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
| Daignault, S; Dy, GK; Gadgeel, SM; Kalemkerian, GP; Ramnath, N; Schneider, BJ; Wozniak, AJ | 1 |
| Bruzzone, M; Centurioni, MG; Cosso, M; Cristoforoni, P; Ferrarini, M; Giannelli, F; Giglione, P; Gualco, M; Merlo, DF; Miglietta, L | 1 |
| Abedallaa, N; Baey, C; Besse, B; de Montpreville, VT; Fabre, D; Guigay, J; Pechoux, CL; Pignon, JP; Planchard, D; Soria, JC; Tremblay, L | 1 |
| Boudou-Rouquette, P; Cessot, A; Coriat, R; Durand, JP; Gaillard, R; Giroux, J; Goldwasser, F; Mir, O; Ropert, S | 1 |
| Couvelard, A; Gillet, A; Goujon, G; Hammel, P; Hentic, O; Lévy, P; Maire, F; Palazzo, M; Rebours, V; Ruszniewski, P; Zappa, M | 1 |
| Buyukberber, S; Elkiran, ET; Gumusay, O; Inal, A; Isikdogan, A; Kaplan, MA; Kucukoner, M; Ozdemir, N; Ulas, A; Unal, O; Urakci, Z; Yaman, S | 1 |
| Levy, B; Saxena, A; Schneider, BJ | 1 |
| Ganti, AK; West, WW; Zhen, W | 1 |
| Boikos, SA; Brahmer, JR; Ettinger, DS; Forde, PM; Giaccone, G; Hann, CL; Hooker, CM; Illei, PB; Kelly, RJ; Petrini, I; Rudin, CM; Yang, SC | 1 |
| Hassan, U; Mozayani, B; Wong, NA | 1 |
| Bunne, M; Fosså, SD; Gundersen, POM; Osnes, T; Skalleberg, J; Småstuen, MC; Solheim, O | 1 |
| Chen, L; Chen, Y; Zhong, D | 1 |
| Ahn, JS; Ahn, MJ; Jung, SH; Kim, BS; Kim, HG; Lee, KH; Lee, SH; Min, YJ; Park, K; Sun, JM; Yi, SY; Yun, HJ | 1 |
| Fatima, I; Masood, M; Nisar, H; Sattar, A; Shahid, AB | 1 |
| Hamada, N; Nakanishi, Y; Okamoto, I; Otsubo, K | 1 |
| Gourley, C | 1 |
| Chen, Y; Li, Q; Li, R; Ren, X; Xia, S; Xu, F | 1 |
| Anai, S; Iwama, E; Nakanishi, Y; Okamoto, I; Otsubo, K; Tanaka, K; Yoneshima, Y | 1 |
| Chen, JN; Feng, T; Li, HM; Lin, DX; Ma, F; Tan, W; Xu, BH; Yang, J; Yin, LL; Yuan, P | 1 |
| Goetze, TO | 1 |
| Adjei, AA; Aubry, MC; Bertino, E; Dakhil, SR; Dy, GK; Lee Hann, C; Mandrekar, SJ; Molina, JR; Nieva, JJ; Sachs, BA; Schenk, EL; Schild, SE; Tan, AD; Wadsworth, TW | 1 |
| Escriu, C; Sallam, M; Wong, H | 1 |
| Balakrishnan, A; Kumar, P; Prasanna, BK | 1 |
| Awad, MM; Cheema, PK; Csőszi, T; Ebiana, V; Gottfried, M; Gümüş, M; Kalemkerian, GP; Kato, T; Kim, HR; Luft, A; Luo, Y; Mazieres, J; Navarro, A; Orlandi, FJ; Peters, S; Pietanza, MC; Rodriguez-Abreu, D; Rudin, CM; Wollner, M; Yang, JC | 1 |
| Chen, Y; Dvorkin, M; Garassino, MC; Goldman, JW; Havel, L; Hochmair, MJ; Hotta, K; Ji, JH; Jiang, H; Laud, PJ; Losonczy, G; Özgüroğlu, M; Patel, N; Paz-Ares, L; Poltoratskiy, A; Reinmuth, N; Shire, N; Statsenko, G; Trukhin, D; Voitko, O | 1 |
| Ackermann, C; Califano, R; Ortega-Franco, A; Paz-Ares, L | 1 |
| Ding, HY; Fang, L; Tong, YH; Xin, WX; Xu, GQ; Yang, GN; Zhang, B; Zhong, LK | 1 |
| Chen, B; Lin, J; Peng, J; Xue, L | 1 |
| Horita, N; Katakura, S; Takeshi, K | 1 |
| Goldman, JW; Paz-Ares, L | 1 |
| Xia, D; Xu, X; Yang, W; Zhang, Y | 1 |
| Alonso-Gordoa, T; Brabander, T; Cadiot, G; Caminoa, A; Capdevila, J; Chakrabarty, B; Couvelard, A; Cros, J; de Mestier, L; García Gómez-Muriel, MI; Garcia-Alvarez, A; Hernando, J; Kats-Ugurlu, G; Lamarca, A; Landolfi, S; Manoharan, P; Pavel, ME; Perrier, M; Ronot, M; Van Velthuysen, MF; Walenkamp, AM; Zandee, W | 1 |
| Ding, D; Hu, H; Huang, J; Li, S; Liao, M; Liu, A; Liu, J; Shi, Y; Tian, X; Zhu, Y | 1 |
| Gu, D; Huang, P; Li, M; Lin, S; Luo, S; Rao, X; Wang, C; Weng, X; Xu, X | 1 |
| Fang, Z; He, M; Liu, M; Liu, Q; Peng, J; Wei, Y; Wu, B; Yi, F; Zhang, W | 1 |
| Economidou, SC; Fotopoulos, G; Vrontis, K | 1 |
| Abdel-Rahman, O; Koski, SL | 1 |
| Li, J; Liu, Q; Luo, X; Peng, L; Tan, C; Wan, X; Yi, L; Zeng, X | 1 |
| Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Inoue, Y; Inui, N; Karayama, M; Nakamura, Y; Suda, T; Suzuki, Y; Watanabe, H; Yasui, H | 1 |
| Bondarenko, I; Chen, Y; Conev, N; Dalvi, TB; Garassino, MC; Goldman, JW; Havel, L; Hochmair, MJ; Hotta, K; Ji, JH; Jiang, H; Losonczy, G; Mann, H; Musso, E; Özgüroğlu, M; Paz-Ares, L; Poltoratskiy, A; Reinmuth, N; Statsenko, G; Trukhin, D; Voitko, O | 1 |
| Chang, CH; Chang, YL; Chen, JS; Hsu, FM; Huang, YL; Lee, JM; Lin, CC; Ma, WL; Yang, JC | 1 |
| Hu, Z; Liao, J; Liu, C; Sun, S; Wang, H; Wang, J; Wu, X; Yu, H; Zhang, Y; Zhao, X | 1 |
| An, J; Cao, L; Chen, C; Deng, P; Gu, Q; He, B; Hu, C; Jiang, J; Li, M; Qin, L; Yang, H | 1 |
| Hara, S; Hata, A; Komatsu, M; Ninomaru, T | 1 |
| Chen, Q; Huang, J; Lin, L; Lv, D; Pan, W; Wu, G; Wu, X; Yan, S | 1 |
| Baudin, E; Beaulaton, C; Blanchet, O; Chatelain, D; Do Cao, C; Ducreux, M; Faron, M; Hadoux, J; Hautefeuille, V; Hervieu, V; Hescot, S; Joubert Zakeyh, J; Kanaan, C; Laboureau, S; Leteurtre, E; Lombard-Bohas, C; Marchal, A; Perrier, M; Petorin, C; Rousselet, MC; Scoazec, JY; Tauveron, I; Walter, T | 1 |
| Arnold, HU; Friesen, TJ; Garrison, SM; Hiatt, JB; Houghton, AM; Liao, SY; MacPherson, D; Martins, R; Norton, JP; Rienhoff, HY; Sandborg, H; Srivastava, S; Sutherland, KD; Wu, F | 1 |
| Imai, H; Kaburagi, T; Kagamu, H; Kaira, K; Kanazawa, K; Kishikawa, T; Masubuchi, K; Minato, K; Minemura, H; Nagai, Y; Shiihara, J; Shiono, A; Takechi, H; Taniguchi, H; Tsuda, T; Umeda, Y; Wasamoto, S; Yamada, Y | 1 |
| Albers, D; Kasper, S; Lahner, H; Markus, P; Mende, B; Mika, S; Reis, H; Rosery, V; Schmid, KW; Schuler, M; Schumacher, B; Siveke, JT; Stuschke, M; Treckmann, J; Wiesweg, M | 1 |
| Chen, L; Chen, Y; Deng, P; Dong, Y; Han, B; Kong, T; Liu, D; Qian, F; Yang, H; Zhang, B; Zhang, W; Zhang, Y | 1 |
| Chang, GC; Chen, KC; Hsu, KH; Huang, JW; Huang, YH; Tseng, JS; Wu, JJ; Yang, TY | 1 |
| Kang, HS; Kim, JW; Kim, SJ; Kim, SK; Lee, SH; Lim, JU; Shin, AY; Yeo, CD | 1 |
| Adamo, V; Cantale, O; Castorina, L; Chillari, F; Colarossi, C; Esposito, F; Franchina, T; Giuffrida, D; Puliafito, I; Ricciardi, GRR; Russo, A; Sciacca, D; Vitale, MP | 1 |
| Eom, JS; Jo, EJ; Kim, KU; Kim, MH; Kim, SH; Lee, K; Lee, MK; Mok, J; Park, HK | 1 |
| Kimura, T; Kurita, T; Miyoshi, AI; Ueda, Y; Yoshino, K | 1 |
| Chen, M; Han, H; Lin, X; Lv, T; Qiu, G; Song, Y; Xie, J; Xu, K; Ye, J; Zhan, P | 1 |
| Deng, W; Dong, X; Jiang, L; Li, L; Liao, A; Min, Y; Shi, A; Yang, D; Yu, H; Yu, R; Zhao, J | 1 |
| Alamgeer, M; Cain, JE; Chen, J; DeVeer, M; Ganju, V; Garama, DJ; Gough, DJ; Guanizo, AC; Inampudi, C; Jakasekara, WSN; Luong, Q; Thakur, N; Watkins, DN | 1 |
| Ni, J; Si, X; Wang, H; Zhang, L; Zhang, X | 1 |
| Chihara, Y; Date, K; Harada, T; Ishida, M; Iwasaku, M; Kanda, H; Kim, YH; Morimoto, K; Shiotsu, S; Takayama, K; Takeda, T; Takemura, Y; Tamiya, N; Tokuda, S; Yamada, T; Yoshimura, A | 1 |
| Artaç, M; Bozcuk, H; Eser, İ; Mutlu, H | 1 |
| Gu, X; Guan, Y; Hao, Y; Song, Z; Sun, Y; Wang, W; Xiang, J; Yao, Q; Zeng, X | 1 |
| Agarwal, M; Almquist, D; Ernani, V; Langlais, BT; Leventakos, K; Liu, A; Manochakian, R; Yu, NY | 1 |
| Arriola, E; Cruz-Castellanos, P; Dómine, M; García-Campelo, R; Insa, A; Juan Vidal, O; Morán, T; Reguart, N; Sullivan, I; Zugazagoitia, J | 1 |
| Akagi, K; Dotsu, Y; Fukuda, M; Gyotoku, H; Hayashi, F; Hisamatsu, Y; Ikeda, T; Kinoshita, A; Morinaga, R; Mukae, H; Nagashima, S; Nakatomi, K; Ogata, R; Ono, S; Senju, H; Shimada, M; Soda, H; Sugasaki, N; Tagawa, R; Takemoto, S; Taniguchi, H; Tomono, H; Umeyama, Y | 1 |
| Hara, Y; Hashimoto, H; Horita, N; Kaneko, A; Kaneko, T; Kobayashi, N; Kubo, S; Kudo, M; Matsumoto, H; Somekawa, K; Teranishi, S; Watanabe, K | 1 |
| Gerner-Rasmussen, J; Hansen, O; Holm, B; Jeppesen, N; Langer, SW; Mau-Sørensen, M; McCulloch, T; Nielsen, HA; Nyhus, CH; Rytter, C; Wedervang, K | 1 |
| Dai, G; Gao, M; Hu, J; Li, L; Ma, J; Wang, Y; Yan, H; Yang, X; Zhang, X; Zhao, Y | 1 |
10 review(s) available for platinum and etoposide
| Article | Year |
|---|---|
[Second-line chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids | 2005 |
Systemic therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Lung Neoplasms; Platinum; Recurrence; Small Cell Lung Carcinoma | 2013 |
Current concepts in the management of small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Platinum; Randomized Controlled Trials as Topic; Recurrence; Small Cell Lung Carcinoma; Treatment Outcome | 2013 |
Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Irinotecan; Network Meta-Analysis; Platinum; Small Cell Lung Carcinoma | 2017 |
Anticancer drug treatment for advanced lung cancer with interstitial lung disease.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Etoposide; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Risk Assessment; Risk Factors | 2018 |
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Male; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2018 |
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2021 |
Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Coordination Complexes; Etoposide; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2021 |
Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Cervix Uteri; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Neoplasm Staging; Platinum; Rare Diseases; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms | 2023 |
First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis.
Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Carboplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Network Meta-Analysis; Platinum; Programmed Cell Death 1 Receptor; Small Cell Lung Carcinoma | 2023 |
19 trial(s) available for platinum and etoposide
| Article | Year |
|---|---|
Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Interactions; Drug Therapy, Combination; Etoposide; Glutathione; Half-Life; Humans; Lung Neoplasms; Mesothelioma; Platinum; Pleural Neoplasms; Time Factors | 1992 |
Oral etoposide is active against platinum-resistant epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma; Drug Resistance; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Treatment Outcome | 1994 |
A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Mesna; Middle Aged; Mitoxantrone; Platinum; Prospective Studies; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure | 1995 |
[Clinical effect of intra-arterial carboplatin-combined chemotherapy for advanced uterine cervical cancer and increased tissue platinum levels with Lipo PGE1 administration before chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Alprostadil; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Cervix Uteri; Chemotherapy, Adjuvant; Epirubicin; Etoposide; Female; Humans; Iliac Artery; Infusions, Intra-Arterial; Infusions, Intravenous; Middle Aged; Mitomycin; Platinum; Uterine Cervical Neoplasms; Vindesine | 1996 |
Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Platinum; Prospective Studies | 1996 |
Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Drug Administration Schedule; Etoposide; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Taxoids; Topotecan | 2005 |
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2011 |
Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Early Termination of Clinical Trials; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Patient Dropouts; Platinum; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2011 |
Second-line treatment with intravenous gemcitabine and oral etoposide in platinum-resistant advanced ovarian cancer patients: results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Survival Analysis; Treatment Outcome | 2011 |
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Etoposide; Female; Humans; Indazoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Platinum; Progression-Free Survival; Pyrimidines; Small Cell Lung Carcinoma; Sulfonamides; Survival Analysis; Treatment Outcome | 2018 |
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Tre
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Double-Blind Method; Etoposide; Humans; Lung Neoplasms; Picornaviridae; Platinum | 2020 |
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Small Cell Lung Carcinoma; Survival Analysis | 2020 |
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Patient Reported Outcome Measures; Platinum; Quality of Life | 2020 |
Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Double-Blind Method; Etoposide; Follow-Up Studies; Humans; Immunotherapy; Lung Neoplasms; Markov Chains; Medicare; Neoplasm Staging; Platinum; Progression-Free Survival; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; United States | 2021 |
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2022 |
A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; China; Etoposide; Humans; Indoles; Lung Neoplasms; Platinum; Prospective Studies; Quinolines; Small Cell Lung Carcinoma | 2022 |
Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Irinotecan; Lung Neoplasms; Platinum | 2023 |
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Etoposide; Humans; Immunotherapy; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2023 |
Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; Topotecan | 2023 |
65 other study(ies) available for platinum and etoposide
| Article | Year |
|---|---|
Overview of early and investigational chemotherapeutic agents in solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Aziridines; Azo Compounds; Camptothecin; Cycloleucine; Etoposide; Floxuridine; Humans; Neoplasms; Nitrogen Mustard Compounds; Picolinic Acids; Platinum; Porfiromycin; Streptonigrin; Teniposide; Thiotepa; Tubercidin | 1976 |
Metastatic choriocarcinoma with coexistent term pregnancy following four recurrent consecutive moles.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Hydatidiform Mole; Lung Neoplasms; Methotrexate; Platinum; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Neoplasms | 1992 |
Clinical experiences with platinum and etoposide therapy in lung cancer.
Topics: Etoposide; Humans; Neoplasms; Platinum | 1992 |
Combination therapy with platinum and etoposide of brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Platinum; Regression Analysis; Remission Induction | 1990 |
Chemotherapeutic approaches to the treatment of testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Dactinomycin; Etoposide; Humans; Male; Platinum; Prognosis; Testicular Neoplasms; Vinblastine | 1988 |
Clinical trials in cancer medicine.
Topics: Adult; Antineoplastic Agents; Bleomycin; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Etoposide; Female; Humans; Male; Methotrexate; Platinum; Tamoxifen; Teniposide; Testicular Neoplasms | 1980 |
Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Cyclophosphamide; Dactinomycin; DNA; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Germinoma; Humans; Leukocytes; Male; Middle Aged; Ovarian Neoplasms; Platinum; Spectrophotometry, Atomic; Testicular Neoplasms; Vinblastine | 1994 |
Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Specimen Collection; Carboplatin; Cisplatin; DNA Adducts; DNA Repair; DNA, Neoplasm; Etoposide; Humans; Kinetics; Leukocytes; Neoplasms; Platinum | 1995 |
Therapeutic dilemma of disseminated CNS germinoma and the potential of increased platinum-based chemotherapy delivery with osmotic blood-brain barrier disruption.
Topics: Adolescent; Adult; Blood-Brain Barrier; Brain; Brain Neoplasms; Carboplatin; Cisplatin; Etoposide; Female; Germinoma; Hearing Loss, High-Frequency; Humans; Magnetic Resonance Imaging; Male; Mannitol; Platinum; Treatment Outcome | 1994 |
Considerations on radiotherapy dose intensity for limited small cell lung cancer.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Etoposide; Humans; Lung Neoplasms; Platinum; Radiotherapy Dosage; Time Factors | 1994 |
Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line.
Topics: Cisplatin; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Glutathione; Humans; Male; Platinum; Teratoma; Testicular Neoplasms; Tumor Cells, Cultured | 1994 |
Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation.
Topics: Animals; Apoptosis; Cell Division; Cell Fractionation; Cisplatin; DNA; DNA Adducts; DNA Damage; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; G2 Phase; Male; Methylprednisolone; Mitosis; Platinum; Rats; Rats, Sprague-Dawley; S Phase; Thymus Gland | 1994 |
Treatment of resistant gestational choriocarcinoma with taxol: a report of two cases.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Choriocarcinoma; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Drug Resistance, Neoplasm; Etoposide; Female; Frontal Lobe; Humans; Liver Neoplasms; Lung Neoplasms; Methotrexate; Middle Aged; Paclitaxel; Platinum; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Neoplasms; Vincristine | 1996 |
[Comparative studies of platinum concentrations in the neck tissues of rats between intraarterial and intravenous infusion of CDDP].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Neck; Platinum; Rats; Rats, Inbred F344; Tissue Distribution | 2002 |
Topotecan as first-line therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Forecasting; Humans; Lung Neoplasms; Paclitaxel; Platinum; Topotecan | 2003 |
Cooperative group research endeavors in small-cell lung cancer: current and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Medical Oncology; Platinum; Radiotherapy, Adjuvant; Small Cell Lung Carcinoma | 2009 |
Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small-cell lung cancer.
Topics: Carboplatin; Cisplatin; Etoposide; Female; Genes; Genome; Humans; Inuit; Lung Neoplasms; Male; Middle Aged; Nerve Tissue Proteins; Platinum; Polymorphism, Single Nucleotide; R-SNARE Proteins; Small Cell Lung Carcinoma | 2010 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Lymph Nodes; Male; Methotrexate; Middle Aged; Neoplasm Staging; Perioperative Care; Platinum; Pneumonectomy; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Aprepitant; Case-Control Studies; Drug Interactions; Drug Therapy, Combination; Etoposide; Female; Humans; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Platinum; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Vomiting | 2012 |
FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Carcinoma, Neuroendocrine; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Pancreatic Neoplasms; Pelvic Neoplasms; Platinum; Treatment Outcome | 2012 |
Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Etoposide; Female; Humans; Male; Medical Oncology; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2012 |
Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Primary combined neuroendocrine carcinoma (small-cell type) and squamous cell carcinoma of the colon.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Neuroendocrine; Carcinoma, Squamous Cell; Colon; Colonic Neoplasms; Etoposide; Fatal Outcome; Humans; Male; Platinum; Point Mutation; Proto-Oncogene Proteins p21(ras); Tomography, X-Ray Computed | 2016 |
Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Audiometry, Pure-Tone; Bleomycin; Case-Control Studies; Chemotherapy, Adjuvant; Child; Cisplatin; Etoposide; Female; Hearing Loss; Humans; Longitudinal Studies; Middle Aged; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Ovariectomy; Platinum; Vinblastine; Young Adult | 2017 |
Disease Characteristics and Treatment Outcome of Testicular Germ Cell Tumors Treated with Platinum-Based Regimens.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Male; Neoplasms, Germ Cell and Embryonal; Platinum; Remission Induction; Testicular Neoplasms; Treatment Outcome | 2018 |
Apatinib and etoposide: surprising efficacy of an oral combination.
Topics: Etoposide; Female; Humans; Ovarian Neoplasms; Platinum; Prospective Studies; Pyridines | 2018 |
Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Genotype; Glucuronosyltransferase; Humans; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Small Cell Lung Carcinoma | 2018 |
[Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA-Directed DNA Polymerase; Etoposide; Genetic Variation; Humans; Lung Neoplasms; Platinum; Polymorphism, Single Nucleotide; Prognosis; Regression Analysis; Small Cell Lung Carcinoma; Treatment Outcome | 2019 |
Immunotherapy: a new era in small-cell lung cancer.
Topics: Antibodies, Monoclonal; Etoposide; Humans; Immunotherapy; Lung Neoplasms; Platinum | 2019 |
Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome; United Kingdom | 2019 |
Circulating tumor cell clusters and circulating tumor cell-derived explant models as a tool for treatment response.
Topics: Animals; Antineoplastic Agents; Blood Cells; Disease Progression; Etoposide; Humans; Mice, Nude; Neoplastic Cells, Circulating; Platinum; Small Cell Lung Carcinoma | 2020 |
Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Etoposide; Female; Humans; Male; Markov Chains; Neoplasm Staging; Platinum; Progression-Free Survival; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2022 |
Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2021 |
Combination treatment options for small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Etoposide; Humans; Lung Neoplasms; Platinum | 2021 |
Combination treatment options for small-cell lung cancer - Authors' reply.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Etoposide; Humans; Lung Neoplasms; Platinum | 2021 |
The Immunosuppression of Etoposide Deserves Attention in Chemoimmunotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Immunosuppression Therapy; Lung Neoplasms; Platinum; Prognosis; Small Cell Lung Carcinoma; Survival Rate | 2021 |
Treatment outcomes of advanced digestive well-differentiated grade 3 NETs.
Topics: Adenocarcinoma; Etoposide; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Platinum; Retrospective Studies; Somatostatin; Treatment Outcome | 2021 |
Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; United States | 2021 |
First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
Topics: Aged; Antibodies, Monoclonal; Cost-Benefit Analysis; Etoposide; Humans; Lung Neoplasms; Medicare; Platinum; Small Cell Lung Carcinoma; United States | 2021 |
Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Prospective Studies; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2022 |
Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum | 2022 |
Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Progression-Free Survival; Retrospective Studies | 2021 |
Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Liver Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Thymoma; Thymus Neoplasms | 2022 |
Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial.
Topics: Brain Neoplasms; Etoposide; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Platinum; Quinolines; Small Cell Lung Carcinoma | 2022 |
Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Small Cell; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors; Small Cell Lung Carcinoma | 2022 |
Toripalimab and anlotinib as a maintenance treatment for extensive-stage small-cell lung cancer: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Indoles; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Quinolines; Small Cell Lung Carcinoma | 2022 |
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum; Prognosis; Retrospective Studies | 2022 |
Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
Topics: Animals; Cell Death; Enzyme Inhibitors; Etoposide; Histone Demethylases; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lysine; Mice; Platinum; Small Cell Lung Carcinoma; Tumor Microenvironment | 2022 |
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2022 |
Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy.
Topics: Etoposide; Gastrointestinal Neoplasms; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Platinum; Prognosis; Retrospective Studies; Stomach Neoplasms | 2023 |
Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Prospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2022 |
Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide-platinum-atezolizumab treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2022 |
Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
Topics: Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Lung; Lung Neoplasms; Neuroendocrine Tumors; Platinum; Retrospective Studies | 2023 |
Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Lung Neoplasms; Platinum; Programmed Cell Death 1 Receptor; Propensity Score; Small Cell Lung Carcinoma | 2023 |
First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Immunotherapy; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Topics: Animals; Etoposide; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Platinum; Proto-Oncogene Proteins c-myc; Small Cell Lung Carcinoma | 2023 |
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Early Detection of Cancer; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Prognosis; Small Cell Lung Carcinoma | 2023 |
The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neuroendocrine Tumors; Platinum; Retrospective Studies | 2023 |
Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2023 |
Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Topics: B7-H1 Antigen; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Programmed Cell Death 1 Receptor; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |